Comparison of the Efficacy and Safety of Three Intravenous Immunoglobulin Brands in Pediatric Patients with Primary Immunodeficiency
Monday, March 7, 2016
South Exhibit Hall H (Convention Center)
Vorapan - Engchuan, MD, Araya Yuenyongviwat, MD, Pasuree Sangsupawanich, MD, PhD

Patients with primary immunodeficiency disease who have hypoglobulinemia need to receive regular immunoglobulin therapy. Each year our hospital changes the brand of IVIG due to government policy. We question how the different brands influence either the trough level of IgG or the rate of infection. The aim of the study was to evaluate the trough levels of IgG and the infection rates of three IVIG brands


This was a retrospective study of the past three years to compare the efficacy of three IVIG brands (Liv-gamma, Gammarass and IV-globulin SN) at Songklanagarind Hospital in primary immunodeficiency patients. The medical records of patients who received regular doses of the three brands of IVIG every 3-4 weeks were reviewed. Each brand had a one-year treatment period. The data collected included the patient characteristics, trough levels of IgG, infections during treatment and adverse effects.


The data of ten primary immunodeficiency patients were collected. Different trough levels of IgG were found in all three brands at visit 6 (Liv-gamma 857.8 mg/dL, Gammarass 821.9 mg/dL, IV-globulin SN 1051.3 mg/dL) (p=0.01). There were no statistical differences in the infection rates among the three brands (Liv-gamma 22%, Gammarass 11%, IV-globulin SN 33%). Adverse reactions occurred in only one patient who received Gammarass. 


The results confirmed that different IVIG brands influenced the trough levels. But the infection rates were in discordance with the trough levels. Maybe there were other factors that influenced the infection rates such as the constancy of the trough levels. This should be evaluated further.